Zobrazeno 1 - 10
of 116
pro vyhledávání: '"Mels, Hoogendoorn"'
Autor:
Jacobien R. Hilberink, Isabelle A. van Zeventer, Dana A. Chitu, Thomas Pabst, Saskia K. Klein, Georg Stussi, Laimonas Griskevicius, Peter J. M. Valk, Jacqueline Cloos, Arjan A. van de Loosdrecht, Dimitri Breems, Danielle van Lammeren-Venema, Rinske Boersma, Mojca Jongen-Lavrencic, Martin Fehr, Mels Hoogendoorn, Markus G. Manz, Maaike Söhne, Rien van Marwijk Kooy, Dries Deeren, Marjolein W. M. van der Poel, Marie Cecile Legdeur, Lidwine Tick, Yves Chalandon, Emanuele Ammatuna, Sabine Blum, Bob Löwenberg, Gert J. Ossenkoppele, Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON), Swiss Group for Clinical Cancer Research (SAKK), Gerwin Huls
Publikováno v:
Blood Cancer Journal, Vol 13, Iss 1, Pp 1-9 (2023)
Abstract Treatment choice according to the individual conditions remains challenging, particularly in older patients with acute myeloid leukemia (AML) and high risk myelodysplastic syndrome (MDS). The impact of performance status, comorbidities, and
Externí odkaz:
https://doaj.org/article/71614de5d82b474e855269ada1ea2dee
Autor:
Johanne Rozema, Mels Hoogendoorn, Iris Potma, Inge tenSeldam, Nic J. G. M. Veeger, Robby E. Kibbelaar, Arjan A. van deLoosdrecht, Eric N. vanRoon, the HemoBase Population Registry Consortium
Publikováno v:
eJHaem, Vol 3, Iss 3, Pp 775-784 (2022)
Abstract The a priori risk for infections in patients with myelodysplastic syndromes (MDS) is unknown. This study examines prescription rates of anti‐infective agents in MDS patients before and after diagnosis, in both in‐ and outpatient settings
Externí odkaz:
https://doaj.org/article/dce0f2b0252a479c8d785c1494dc8574
Autor:
Camille C.B. Kockerols, Inge G.P. Geelen, Mark-David Levin, Jeroen J.W.M. Janssen, H. Berna Beveloo, Avinash G. Dinmohamed, Mels Hoogendoorn, Jan J. Cornelissen, Peter E. Westerweel
Publikováno v:
Haematologica, Vol 108, Iss 11 (2023)
Externí odkaz:
https://doaj.org/article/6971dd1f39964a23b1030f8a92664d5d
Autor:
Camille C.B. Kockerols, Inge Geelen, Mark-David Levin, Jeroen J.W.M. Janssen, Avinash G. Dinmohamed, Mels Hoogendoorn, Jan J. Cornelissen, Peter E. Westerweel
Publikováno v:
Haematologica, Vol 107, Iss 8 (2022)
Externí odkaz:
https://doaj.org/article/3cbfc3e6e6b04dc2b2b47892ce1b6b31
Autor:
Simone Oerlemans, Lindy Paulina Johanna Arts, Jacobien M Kieffer, Judith Prins, Mels Hoogendoorn, Marjolein van der Poel, Ad Koster, Chantal Lensen, Wendy Bernadina Catharina Stevens, Djamila Issa, Johannes F M Pruijt, Margriet Oosterveld, René van der Griend, Marten Nijziel, Lidwine Tick, Eduardus F M Posthuma, Lonneke V van de Poll-Franse
Publikováno v:
Journal of Medical Internet Research, Vol 23, Iss 12, p e27886 (2021)
BackgroundThere has been a cultural shift toward patient engagement in health, with a growing demand from patients to access their results. ObjectiveThe Lymphoma Intervention (LIVE) trial is conducted to examine the impact of return of individual pa
Externí odkaz:
https://doaj.org/article/ae41c730ec3c45a08f0de065084a08a3
Publikováno v:
BMC Infectious Diseases, Vol 19, Iss 1, Pp 1-4 (2019)
Abstract Background Patients with multiple myeloma (MM) are known to be immune incompetent and experience higher incidences of infectious diseases. However, infective endocarditis (IE) is rarely observed in patients with MM and Morganella morganii (M
Externí odkaz:
https://doaj.org/article/8b55d8010964457dafaac51dc2175f0a
Autor:
Iris de Weerdt, Tom Hofland, Renate de Boer, Johan A. Dobber, Julie Dubois, Denise van Nieuwenhuize, Mehrdad Mobasher, Fransien de Boer, Mels Hoogendoorn, Gerjo A. Velders, Marjolein van der Klift, Ester B.M. Remmerswaal, Frederike J. Bemelman, Carsten U. Niemann, Sabina Kersting, Mark-David Levin, Eric Eldering, Sanne H. Tonino, Arnon P. Kater
Publikováno v:
Blood Advances, Vol 3, Iss 17, Pp 2642-2652 (2019)
Abstract: Morbidity and mortality due to immunosuppression remain among the foremost clinical challenges in chronic lymphocytic leukemia (CLL). Although immunosuppression is considered to originate within the lymph node (LN) microenvironment, alterat
Externí odkaz:
https://doaj.org/article/9b70facd4d2e4144a9ac742f72e1a6b0
Autor:
Johanne, Rozema, Ivar, van Asten, Beau, Kwant, Robby E, Kibbelaar, Nic J G M, Veeger, Harry, de Wit, Eric N, van Roon, Mels, Hoogendoorn
Publikováno v:
European Journal of Haematology, 109(6), 772-778. Wiley
OBJECTIVES: In patients with myelodysplastic syndromes (MDS) with >20 transfusions and ferritin levels >1000 μg/L, international guidelines recommend iron chelation therapy (ICT). The study's objective was to determine guideline adherence and the in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2175c6bd54def0087478050c5b5c7652
https://doi.org/10.1111/ejh.13865
https://doi.org/10.1111/ejh.13865
Autor:
Arnon P. Kater, Marinus H.J. van Oers, Yvette van Norden, Lina van der Straten, Julia Driessen, Ward F.M. Posthuma, Martin Schipperus, Martine E.D. Chamuleau, Marcel Nijland, Jeanette K. Doorduijn, Michel Van Gelder, Mels Hoogendoorn, Francien De Croon, Shulamiet Wittebol, J. Martijn Kerst, Erik W.A. Marijt, Reinier A.P. Raymakers, Martijn R. Schaafsma, Johan A. Dobber, Sabina Kersting, Mark-David Levin
Publikováno v:
Haematologica, Vol 104, Iss 1 (2019)
Lenalidomide has been proven to be effective but with a distinct and difficult to manage toxicity profile in the context of chronic lymphocytic leukemia, potentially hampering combination treatment with this drug. We conducted a phase 1-2 study to ev
Externí odkaz:
https://doaj.org/article/fd2f85f1135842ee993a2e9b722ce63a
Autor:
Barbara Eichhorst, Carsten U. Niemann, Arnon P. Kater, Moritz Fürstenau, Julia von Tresckow, Can Zhang, Sandra Robrecht, Michael Gregor, Gunnar Juliusson, Patrick Thornton, Philipp B. Staber, Tamar Tadmor, Vesa Lindström, Caspar da Cunha-Bang, Christof Schneider, Christian B. Poulsen, Thomas Illmer, Björn Schöttker, Thomas Nösslinger, Ann Janssens, Ilse Christiansen, Michael Baumann, Henrik Frederiksen, Marjolein van der Klift, Ulrich Jäger, Maria B.L. Leys, Mels Hoogendoorn, Kourosh Lotfi, Holger Hebart, Tobias Gaska, Harry Koene, Lisbeth Enggaard, Jereon Goede, Josien C. Regelink, Anouk Widmer, Florian Simon, Nisha De Silva, Anna-Maria Fink, Jasmin Bahlo, Kirsten Fischer, Clemens-Martin Wendtner, Karl A. Kreuzer, Matthias Ritgen, Monika Brüggemann, Eugen Tausch, Mark-David Levin, Marinus van Oers, Christian Geisler, Stephan Stilgenbauer, Michael Hallek
Publikováno v:
Eichhorst, B, Niemann, C U, Kater, A P, Fürstenau, M, von Tresckow, J, Zhang, C, Robrecht, S, Gregor, M, Juliusson, G, Thornton, P, Staber, P B, Tadmor, T, Lindström, V, da Cunha-Bang, C, Schneider, C, Poulsen, C B, Illmer, T, Schöttker, B, Nösslinger, T, Janssens, A, Christiansen, I, Baumann, M, Frederiksen, H, van der Klift, M, Jäger, U, Leys, M B L, Hoogendoorn, M, Lotfi, K, Hebart, H, Gaska, T, Koene, H, Enggaard, L, Goede, J, Regelink, J C, Widmer, A, Simon, F, De Silva, N, Fink, A-M, Bahlo, J, Fischer, K, Wendtner, C-M, Kreuzer, K A, Ritgen, M, Brüggemann, M, Tausch, E, Levin, M-D, van Oers, M, Geisler, C, Stilgenbauer, S, Hallek, M, German CLL Study Group (GCLLSG), Haemato-Oncology Foundation for Adults in the Netherlands (HOVON), Nordic CLL Study Groups, Swiss Group for Clinical Cancer Research (SAKK), The Israeli CLL Association & Cancer Trials Ireland 2023, ' First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia ', The New England Journal of Medicine, vol. 388, no. 19, pp. 1739-1754 . https://doi.org/10.1056/NEJMoa2213093
BACKGROUNDRandomized trials of venetoclax plus anti-CD20 antibodies as first-line treatment in fit patients (i.e., those with a low burden of coexisting conditions) with advanced chronic lymphocytic leukemia (CLL) have been lacking.METHODSIn a phase
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::57065540dd32adf0cc1d031449d13807
https://vbn.aau.dk/da/publications/3cae35e7-c81b-42b3-8598-001ac74af83e
https://vbn.aau.dk/da/publications/3cae35e7-c81b-42b3-8598-001ac74af83e
